<DOC>
	<DOCNO>NCT02227394</DOCNO>
	<brief_summary>This study conduct randomize , double blind , double dummy two-period crossover study stable asthma patient treat accordance Global Initiative Asthma ( GINA ) guideline , include . The primary objective study evaluate effect product investigation Functional respiratory image parameter evaluate particle deposition Computational fluid dynamic ( CFD ) .The secondary objective study assess effect Z7200 Symbicort® lung function ( spirometry body plethysmography ) , exercise capacity ( 6MWT ) dyspnea ( Borg CR10 Scale VAS dyspnea ) . Furthermore safety 2 product investigation evaluate monitoring adverse event throughout study .</brief_summary>
	<brief_title>Study Compare Effects Z7200 And Symbicort® Turbohaler Respiratory Imaging Parameters Asthmatic Patients</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<criteria>1 . Male female patient ≥ 18 year old . 2 . Written inform consent obtain . 3 . Patient document diagnosis asthma accord Global Initiative Asthma ( GINA ) guideline 4 . Patient cooperative attitude ability correctly use DPI . 5 . Female patient childbearing potential confirm reliable method contraception use least 14 day visit 1 continue use reliable method contraception study , postmenopausal woman ( least 12 month amenorrhea ) 6 . Patient must stable treated accordance GINA guideline . 7 . Patient must nonsmoker exsmoker stop smoke least 1 month prior visit 1 smoke history &lt; 10 pack year . 8 . Patient must able understand complete protocol requirement , instruction , questionnaire protocolstated restriction . 1 . Pregnant lactate female . 2 . Unstable patient develop asthma exacerbation 4 week screen . 3 . Patient upper low airway infection 4 week screen . 4 . Patient unable perform pulmonary function test . 5 . Patients unable withdraw fix combination long act bronchodilator inhalation product 6 . Patient uncontrolled disease condition might , judgement investigator , place patient undue risk potentially compromise result interpretation study . 7 . Patient active lung cancer chronic disease poor prognosis /or affect patient status . 8 . Patient allergy , sensitivity intolerance study drug and/ study drug formulation ingredient . 9 . Patient unlikely comply protocol unable understand nature , scope possible consequence study . 10 . Patient receive systemic corticosteroid within last 4 week prior visit 11 . Patient receive investigational new drug within last 4 week prior visit 1 participate clinical trial . 12 . Patient history alcohol substance abuse opinion investigator may clinical significance 13 . Patient diagnosis Chronic Obstructive Pulmonary Disease ( COPD ) . 14 . Patients lactose intolerance history allergy milk protein . 15 . Patients treat medication herbal medicine strong cytochrome P450 3A4 ( CYP3A4 ) inhibitor ( e.g. , ritonavir , indinavir , nelfinavir , saquinavir , atazanavir , ketoconazole , itraconazole , voriconazole , fluconazole , cyclosporine , mibefradil , nefazodone , clarithromycin , telithromycin , troleandromycin , norfloxacin , ciprofloxacin ) inducer ( e.g . phenobarbital , phenytoin , barbiturate , carbamazepine , oxcarbazepine , rifabutin , rifampin , St John 's wort ) within 2 week prior Screening Visit study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Functional Respiratory Imaging</keyword>
	<keyword>Computational Fluid Dynamic</keyword>
</DOC>